AMASA Therapeutics
Company Type: Therapeutics
Main focus: High-grade glioblastoma (GBM)
Company stage: Pre-clinical
Diseases: Diverse cancers
Genome-editing tool: CRISPR-Cas9
Funding stage: Pre-seed
Location: Boston, USA
Website: https://www.amasatx.com/
Pipeline:
Partners:
AMASA Therapeutics is an early-stage biopharmaceutical company focused on the development of novel stem cell-based targeted biological therapies to treat cancer patients with unmet need. The company's platform technology includes encapsulated engineered allogeneic receptor-targeted cell-based therapeutics, and a proprietary procedure developed by the focal cancer therapy pioneer and inventor, Khalid Shah, MS, PhD., Professor at Harvard Medical School and Vice Chairman of Research at BWH-Neurosurgery.